Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F, Arnold D, Golfieri R, Pech M, Peynircioglu B, Pfammatter T, Ronot M, Sangro B, Schaefer N, Maleux G, Munneke G, Pereira H, Zeka B, de Jong N, Helmberger T; CIRT Principal Investigators. Kolligs F, et al. JHEP Rep. 2022 Nov 25;5(2):100633. doi: 10.1016/j.jhepr.2022.100633. eCollection 2023 Feb. JHEP Rep. 2022. PMID: 36593888 Free PMC article.
Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study.
Maleux G, Albrecht T, Arnold D, Bargellini I, Cianni R, Helmberger T, Kolligs F, Munneke G, Peynircioglu B, Sangro B, Schaefer N, Pereira H, Zeka B, de Jong N, Bilbao JI; CIRT Principal Investigators. Maleux G, et al. Among authors: kolligs f. Cardiovasc Intervent Radiol. 2023 Jul;46(7):852-867. doi: 10.1007/s00270-023-03391-4. Epub 2023 Mar 13. Cardiovasc Intervent Radiol. 2023. PMID: 36914788 Free PMC article.
Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT.
Schaefer N, Grözinger G, Pech M, Pfammatter T, Soydal C, Arnold D, Kolligs F, Maleux G, Munneke G, Peynircioglu B, Sangro B, Pereira H, Zeka B, de Jong N, Helmberger T; CIRT Principal Investigators. Schaefer N, et al. Among authors: kolligs f. Clin Colorectal Cancer. 2022 Dec;21(4):285-296. doi: 10.1016/j.clcc.2022.09.002. Epub 2022 Sep 20. Clin Colorectal Cancer. 2022. PMID: 36270925 Free article.
Loss of DRO1/CCDC80 in the tumor microenvironment promotes carcinogenesis.
Christian JI, Pastula A, Herbst A, Neumann J, Marschall MK, Ofner A, Zierahn H, Schneider MR, Wolf E, Quante M, Kolligs FT. Christian JI, et al. Among authors: kolligs ft. Oncotarget. 2022 Apr 11;13:615-627. doi: 10.18632/oncotarget.28084. eCollection 2022. Oncotarget. 2022. PMID: 35422964 Free PMC article.
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M; SORAMIC study group. Öcal O, et al. Cancer Imaging. 2022 Jan 4;22(1):1. doi: 10.1186/s40644-021-00439-x. Cancer Imaging. 2022. PMID: 34983668 Free PMC article.
Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers.
Koch C, Göller M, Schott E, Waidmann O, Op den Winkel M, Paprottka P, Zangos S, Vogl T, Bechstein WO, Zeuzem S, Kolligs FT, Trojan J. Koch C, et al. Among authors: kolligs ft. Cancers (Basel). 2021 Apr 28;13(9):2121. doi: 10.3390/cancers13092121. Cancers (Basel). 2021. PMID: 33924810 Free PMC article.
119 results